Vandetanib shows clinical benefit when combined with docetaxel for lung cancer

Links shared publicly online about this topic.

  • 2,001
    total visits

Vandetanib shows clinical benefit when combined with docetaxel for lung cancer

physorg.com

When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research from The University of Texas M. D. Anderson Cancer Center.

View full resource at physorg.com

Tags: Cancer, Cancer Medication, Chemotherapy, Lung Cancer, Non-Small Cell Lung Cancer, Lung, Taxotere

  • Share

Most Recently Shared on June 5, 2010 at 6:56 am By:

FightCancer FightCancer

Vandetanib shows clinical benefit when combined with docetaxel for lung cancer http://tinyurl.com/lqswv2

3 years ago...

Vandetanib shows clinical benefit when combined with docetaxel for lung cancer - News

virtualmedicalcentre.com — “When combined with standard chemotherapy, the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer.View full resource at virtualmedicalcentre.com

  • View Related
  • Share

Most Recently Shared on June 21, 2010 at 2:09 pm By:

VirtualMedical VirtualMedicalCentre Health Site

Vandetanib shows clinical benefit when combined with docetaxel for lung cancer http://dlvr.it/1vTQF

2 years ago...

Vandetanib shows clinical benefit for lung cancer: When combined with standard chemotherapy, an international Phas... http://bit.ly/cPXe1t

medicineworld.org — “Vandetanib shows clinical benefit for lung cancer: When combined with standard chemotherapy, an international Phas... http://bit.ly/cPXe1tView full resource at medicineworld.org

  • View Related
  • Share

Most Recently Shared on June 7, 2010 at 7:15 pm By:

LungCancer Lung Cancer OW OW Health

Vandetanib shows clinical benefit for lung cancer: When combined with standard chemotherapy, an international Phas... http://bit.ly/cPXe1t

2 years ago...

Advertisement